01887nas a2200277   4500000000100000008004100001260001200042653001400054653001400068653002000082653001200102653001800114653002700132100001600159700001500175700001500190700001400205700001100219700001800230700001300248245015000261300001100411490000800422520116500430022001401595       2021                            d  c01/202110aBacterial10adiagnosis10aDrug resistance10aleprosy10aMeta-analysis10aSequence analysis, DNA1 aAndrade ESN1 aBrandão J1 ada Silva J1 aKurizky P1 aRosa P1 ade Araújo WN1 aGomes CM00aA systematic review and meta-analysis of studies on the diagnostic accuracy and screening of tests to detect antimicrobial resistance in leprosy.  a1153250 v1003 a<p>Although multidrug therapy is considered an effective treatment for leprosy, antimicrobial resistance is a serious concern. We performed a systematic review of studies on the diagnostic accuracy and screening of tests for antimicrobial resistance in leprosy. This review was registered in PROSPERO (CRD42020177958). In April 2020, we searched for studies in the PubMed, EMBASE, Web of Science, Scopus, Scielo, and LILACS databases. A random effects regression model was used for the meta-analysis. We included 129 studies. Molecular tests for dapsone resistance had a sensitivity of 78.8% (95% confidence interval [CI] = 65.6-87.9) and a specificity of 97.0% (95% CI = 94.0-98.6). Molecular tests for rifampicin resistance had a sensitivity and specificity of 88.7% (95% CI = 80.0-93.9) and 97.3% (95% CI = 94.3-98.8), respectively. Molecular tests for ofloxacin resistance had a sensitivity and specificity of 80.9% (95% CI = 60.1-92.3) and 96.1% (95% CI = 90.2-98.5), respectively. In recent decades, no increase in the resistance proportion was detected. However, the growing number of resistant cases is still a clinical concern.</p>  a1879-0070